Alterity Therapeutics Ltd. · ASX:ATH

Alterity Therapeutics — Investor Presentation (December 2020)

12 slides from Alterity Therapeutics's investor presentation, December 2020

  1. Slide 1: Alterity Therapeutics

    Alterity Therapeutics (NASDAQ:ATHE, ASX:ATH) Geoffrey Kempler, CEO and Chairman December 2020 CONFIDENTIAL 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain some statements that may be considered “Forward-Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to the Company’s plans, objec

  3. Slide 3: Our Purpose

    Our Purpose We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people with these diseases. CONFIDENTIAL 3

  4. Slide 4: Year in Review

    Year in Review Allowance of US patent for next ATH434 crosses blood brain barrier in generation compounds to treat humans; clinically tested doses achieved neurodegenerative diseases concentrations in the brain Raises $35M in placement to European Commission approves Orphan international and Austral

  5. Slide 5: Parkinsonian Disorders − A Significant Unmet Need

    Parkinsonian Disorders − A Significant Unmet Need  Parkinsonism is a syndrome of motor symptoms that includes slowness of movement, stiffness and tremor  Major source of disability  Parkinsonian disorders also include MSA atypical variants such as Multiple system atrophy (MSA) and Parkinson’s Pro

  6. Slide 6: Excellent Progress with Lead Drug Candidate ATH434

    Excellent Progress with Lead Drug Candidate ATH434  Robust efficacy in animal  Completed Phase 1  Qualitative research with models of disease  Orally bioavailable, brain penetrant U.S. neurologists completed  Evidence of neuroprotection with  ATH434: safe and well tolerated  15 movement disor

  7. Slide 7: bioMUSE Natural History Study

    bioMUSE Natural History Study • Design: Observational (no treatment) • Objective: De-risk Phase 2 study • Identify biomarker(s) suitable for endpoint in treatment study • Evaluate the change in biomarkers and clinical manifestations in patients with early MSA to track disease progression • Populatio

  8. Slide 8: Phase 2 Study Design

    Phase 2 Study Design • Design: Randomized, double-blind, placebo controlled • Objectives • Assess target engagement and preliminary efficacy of ATH434 • Evaluate safety and tolerability of ATH434 • Population: Early MSA patients (parkinsonian variant) with motor symptoms ≤ 3 years • Sample size: 60

  9. Slide 9: Commercial Opportunity – Multiple System Atrophy

    Commercial Opportunity – Multiple System Atrophy Independent Analysis STRONG INTENT TO SUBSTANTIAL UNMET NEED PRESCRIBE Severely debilitating, fatal illnesses with Motivated by efficacy in treating the no current treatments are ripe for new underlying disease and not just the entrants targeting what

  10. Slide 10: Leadership of 3 FDA Approvals in Neurology

    Leadership of 3 FDA Approvals in Neurology David Stamler, M.D. Chief Medical Officer FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine for Chorea Associated With Huntington • 3 FDA Approvals in Neurology Disease • Led FDA Advisory Committee and approval of Dec 7, 2007 X

  11. Slide 11: Investment Summary

    Investment Summary  Targeting Orphan disease with no approved treatments • ATH434 has potential U.S. peak sales up to US$ 725 million  Development team with proven track record at FDA  Lead drug candidate ATH434 • Commenced natural history study to inform Phase 2 study • Completed Phase 1 with ex

  12. Slide 12: For further information please contact

    For further information please contact: [email protected]

Alterity Therapeutics — Investor Presentation (December 2020) on 6ix